



Supplementary Fig. 1. Knockout of CCR1 increases response to bortezomib in MM cell lines *in vitro* and *in vivo*. U266 CRISPR-Cas9 CCR1 knockout (U266-CCR1^{KO}) or empty vector (U266-EV) control cells were treated with bortezomib or 0.002% DMSO vehicle control (V) for 24 hours and relative cell number was assessed by WST-1. Graphs depict mean \pm SEM for 7 independent experiments. *** $p < 0.0001$ relative to EV control, two-way ANOVA with Sidak's multiple comparisons test.


p-Jnk



IRE1 α




Tubulin




Supplementary Fig. 2. Uncropped Western blots - OPM2

p-Jnk



IRE1 α



Tubulin

